Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 31 2025
0mins
Source: Globenewswire
Study Launch: Seer, Inc. and Korea University have initiated a groundbreaking study to identify early-onset cancer biomarkers using Seer's Proteograph ONE Assay and advanced mass spectrometry, aiming to analyze 20,000 plasma samples over three years.
Technological Advancements: The Proteograph ONE workflow significantly enhances proteomic analysis efficiency, allowing for rapid processing of samples and identification of more proteins than traditional methods, which could lead to improved cancer diagnostics and treatment strategies for young adults.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like undefined with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
